Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-News
 NHF In The News
 NHF eNotes
 Medical Advisories
 Advocacy and Legislative Updates
-Medical News
 Blood Safety News
 NHF and Community News
 Industry News
 Travel Advisory

 

 

 
FDA Issues New Guidelines for Manufacturers of Biologics
 

On September 29, 2006 the U.S. Food and Drug Administration (FDA) released enhanced guidelines to improve the manufacturing standards of pharmaceutical and human biological drug products. The existing guidelines for manufacturers are called Good Manufacturing Practices. FDA officials anticipate that the new measures will help pharmaceutical companies lower production costs, improve efficiency, prevent drug shortages and recalls, make greater technological advances, and ultimately produce safer and more effective drugs.         

“This guidance incorporates modern quality principles into FDA’s approach to manufacturing, encouraging industry adoption of new technological advances and integrated quality systems,” said Dr. Janet Woodcock, FDA Deputy Commissioner for Operations.

Read the Quality Systems Approaches to Pharmaceutical Current Good Manufacturing Practice (CGMP) Regulations

Source: America’s Blood Centers Newsletter, October 13, 2006

 

This section of our Web site is sponsored by: